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ABSTRACT: Ayahuasca is a psychoactive beverage commonly consumed by indigenous 
people of the Amazon, traditionally used in religious and medicinal rituals. Scientific research 
has recently corroborated the indigenous belief on the beverage’s healing powers when it comes 
to psychoneurological disorders. It was verified that a single dosage of Ayahuasca can help 
lower depression severity in patients resistant to the usual treatments.  Considering the 
epidemic state of the disorder in the present day, there is enormous potential for developing 
new kinds of treatment, which will be enabled through pharmaceutical patents. However, the 
indigenous communities behind those scientific and pharmaceutical studies must not be 
forgotten. In this article, utilizing literature and previous studies to support our views and our 
arguments, we analyze the protection of the traditional medicine and knowledge related to 
Ayahuasca consumption in light of intellectual property rights, as well as the indigenous 
people’s rights to be involved in the results brought by the future pharmaceutical patents 
arising from Ayahuasca exploration. The method used is the deductive and the research 
technique is the bibliographical. It is structured in introduction, development, conclusions and 
bibliography. 
KEYWORDS: Ayahuasca, depression, intellectual property, traditional medicine, traditional 
knowledge, fairtrade 
RESUMO: A Ayahuasca é uma bebida psicoativa, costumeiramente consumida por indígenas 
da Amazônia e tradicionalmente utilizada em rituais religiosos e medicinais. Recente pesquisa 
científica corroborou o credo indígena nos poderes curandeiros da bebida, quando se trata de 
desordens psiconeurológicas. Foi verificado que uma única dose de Ayahuasca pode ajudar a 
diminuir a severidade da depressão em pacientes resistentes aos tratamentos conhecidos 
atualmente. Considerando o estado epidêmico da desordem nos dias atuais, há enorme 
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potencial para o desenvolvimento de novos tratamentos, possibilitados por meio de patentes 
farmacêuticas. Todavia, as comunidades indígenas por trás de tais estudos científicos e 
farmacêuticos não devem ser esquecidas. No presente artigo, utilizando de levantamento de 
literatura e estudos anteriores para apoiar nossa visão e argumentos, nós analisamos a proteção 
dada ao conhecimento e à medicina tradicional relacionados ao consumo da Ayahuasca, sob a 
perspectiva dos direitos de propriedade intelectual, bem como os direitos dos povos indígenas 
de estarem envolvidos nos resultados atingidos pelas futuras patentes farmacêuticas 
provenientes da exploração da Ayahuasca. O método utilizado é o dedutivo e a técnica de 
pesquisa bibliográfica. Se estrutura em introdução, desenvolvimento, conclusões e bibliografia. 
PALAVRAS-CHAVE: Ayahuasca, depressão, propriedade intelectual, medicina tradicional, 
conhecimento tradicional, fairtrade 
SUMMARY: Introduction 1 Traditional Medicine, Intellectual Property Rights And 
Pharmaceutical Patents 1.1 The Situation Of Traditional Medicine In The Last Decades 2 The 
Case Of Ayahuasca Misappropriation 3 Strategies And Legislations On Protecting Traditional 
Medicine 4 Commerce Équitable: Intellectual Property Rights And Autonomy Of Indigenous 
People In Fairtrade Of Traditional Medicine 5 Conclusion References 
 
INTRODUCTION 
Ayahuasca, also known as hoasca, daime, natem or yajè in South American countries such 
as Brazil, Ecuador and Peru, is the infusion of two main natural ingredients: the plants 
Banisteriopsis caapi and Psychotria viridis. In Brazil, these plants are commonly known as the vine 
“mariri” (or “cipó mariri”) and the leaf “chacrona” (or “folha chacrona”), respectively. The brew 
produced by such infusion has psychoactive qualities, reportedly causing hallucinogenic visions of 
various kinds1. Its preparation and consumption can be found in numerous indigenous 
communities throughout the Amazon. Though the components of the infusion may vary2, the 
presence of cipó mariri (B. caapi) is prominent in all variations of the brew. 
For its psychoactive effects, Ayahuasca is considered to be sacred, and it is traditionally 
used as key element in religious and medicinal rituals. The first reports on its use date back prior 
to European appearances in the Americas. Although a ceremonial key element in indigenous 
culture, over the past decades, Ayahuasca consumption has been popularized amongst non-
indigenous people. In Brazil, reports of religious segments that merge Ayahuasca tea with 
Christian perception date back to the early twentieth century34. The popularization of Ayahuasca 
isn’t restrained to Brazil, as European countries such as Germany, Holland and Spain have also 
reported Ayahuasca consumption in urban areas since the late 1990’s5,6. 
While, initially, the popularization of Ayahuasca consumption was seen as a health 
concern, study over the years has shown that the beverage possesses chemical properties that 
might translate into therapeutic potential7,8 ,9. More recently, a study led by Fernanda Palhano-
Fontes et al10 at the Federal University of Rio Grande do Norte (UFRN) found evidence of 
antidepressant efficacy after a session of Ayahuasca dosing in patients who were resistant to the 
usual treatments. The report is significant for the pharmaceutical community: the study of 
Ayahuasca’s pharmacologic potentials can lead to new medicinal settings, as well as new forms of 
treatment and new drugs. And pharmaceutical patents are possibly the next step. 
Pharmaceutical corporations have a history of exploring biological materials sourced 
from countries rich in biological diversity, utilizing these materials, as well as the traditional 
knowledge that often comes with them, to study and create new drugs or other medical 
products11. “Appropriation” is a term often attributed to these practices, given that the source of 
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this kind of knowledge comes from indigenous communities of developing countries, and the 
results of these researches and pharmaceutical patents don’t meet the groups that originally 
detained the knowledge12,13 ,14. 
The controversy surrounding intellectual property rights of the indigenous groups, in 
contrast to the development of medicine, has been a recurring theme over the past few years. In 
this article, we analyze the main controversy surrounding intellectual property rights of indigenous 
people and the pharmaceutical patents that might possibly turn up after the conclusions of recent 
research. Our goal is to point out possible solutions for the controversy so as to balance western 
modern medicine’s need for development and the intellectual property rights regarding 
traditional medicine.  
 
 
1 Traditional Medicine, Intellectual Property Rights And Pharmaceutical Patents 
Intellectual Property Rights (IPRs) correspond to a collection of legal devices in which 
creations are granted with specific legal protection for a certain period15. With its branches of 
conceptualization and applicability, IPRs are a mean to encourage intellectual creations as well as 
social and scientific development, by way of granting benefits such as temporary exclusivity rights 
over exploration, exportation or commercialization of the creation. Here, “creation” can refer to 
any kind of product or implementation made possible by intellectual activity: arts, literature, 
scientific works, inventions, brands, industrial design or even procedures are all examples of what 
can be protected by IPRs. 
While nature discoveries aren’t protected by IPRs (for example, the discovery of a new 
chemical element), when it comes to the medicine field, IPRs often manifest themselves through 
pharmaceutical patents. A patent is the device that allows protection over procedures that utilize 
nature as means to achieve a technique that serves to better a health-related problem16. The key 
word here is “technique”, given that a patent is recognized when a technique is developed, in 
which natural laws or materials are used in the most efficient way possible to achieve a precise 
result. 
It all comes together when we think of the new discovery made by Palhano-Fontes et al. 
The recent confirmation that Ayahuasca has the potential to serve as a treatment for depression 
is incredibly valuable for the medicine field, given the epidemic state of the disorder nowadays17. 
We deliberately call it confirmation because indigenous people have used Ayahuasca as part of 
religious and medicinal rituals for centuries. Although resting on non-scientific forms of 
knowledge, the very idea that the beverage might affect an individual on a neurological level came 
from the traditions of these indigenous people. 
Traditional medicine (TRM), also called non-conventional medicine, is the term used to 
refer to knowledge transmitted culturally, through generations, regarding health or healing 
practices, as conceptualized by the World Health Organization – WHO18. While traditional 
medicine is often credited as a rich source of non-scientific knowledge, literature has 
acknowledged the historical exploration of biological resources and traditional medicine by 
pharmaceutical corporations of developed countries:  
TRM has been recognized in western science as a valuable source of products and 
treatments for health care. It often provides leads for the development and 
commercialization of new pharmaceutical products. However, western intellectual 
property systems have regarded TRM, as well as other components of traditional 
knowledge (TK), as information in the “public domain”, freely available for use by 
anybody. This has meant that TRM and other traditional knowledge has been 
exploited in Western contexts without any recognition, moral or economic, to those 
who originated or held the relevant knowledge. Further, diverse components of TRM 
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have been appropriated under intellectual property rights (IPRs) by researchers and 
commercial enterprises, without any compensation to the knowledge’s creators or 
holders19.  
Indigenous communities are exploited of their knowledge. This knowledge is not so much 
a commercial tool as it is an expression of their culture, their traditions and their religious beliefs. 
To appropriate of that knowledge without so much as a gratification or recognition does not sit 
right with the very idea of intellectual property. If IPRs’ purpose is to celebrate and encourage 
intellectual development, appropriating and patenting traditional knowledge does not seem fair, 
considering that only the final “owner” of the knowledge is granted with the benefits patents can 
bring. 
Usually, agreements for exploring traditional knowledge and biological materials are 
celebrated through contracts20. Although a contract can serve as a legal support for binding 
responsibilities, it is important to observe the balance of power between the parties of the 
contract. In the case of pharmaceutical corporations seeking TK from indigenous communities, the 
lack of balance between each side of the contract is obvious. 
Lo que sucede con este tipo de negociación es que los términos en que se define el 
contrato es el resultado de la correlación de fuerzas entre las partes que participan 
de la negociación. En este caso, el desequilibrio entre laboratorios farmacéuticos y 
comunidades indígenas es claro. Los primeros tienen una amplia experiencia en 
procesos de contratos, mientras que las comunidades tienen escasa o nula 
experiencia ni conocimientos de las estrategias normalmente usadas. Además, el 
laboratorio suele saber qué busca, y puede prever con cierto grado de certeza los 
resultados que obtendrá con el objeto que adquiera. La comunidad indígena ignora 
completamente este resultado. Además, no posee ninguna referencia para medir su 
valor. Como consecuencia, la comunidad suele vender sus conocimientos a precios 
absurdamente bajos.21 
The situation of vulnerability faced by members from traditional communities, whether 
indigenous or not, is noticeable and urgent to address. The recent and unfinished tendencies to 
finally protect this sector of the population, so rich in culture and knowledge, point to the need 
for intervention in our subject: the intellectual property, understood as protecting the right of 
“creators”, their works, knowledge or understandings, which, in this case, are ancestral and, 
consequently, increase their need for preservation, characterization, systematization, adequate 
dissemination and participation of their authors and creators both morally and economically. 
International organizations have been concerned with this topic only from the beginning 
of this century and, although the Nagoya Protocol reflects the aforementioned interest, real 
actions are still few and insufficient, as we will discuss further below. 
 
1.1 The Situation Of Traditional Medicine In The Last Decades 
The Law of Taiwan (Taipei, Republic of China) refers in the article 19 to the invention as 
a high creation of technical concept(s) for which natural laws are used. In fact, it is one of the few 
legislations that define the concept considering nature. 
This country, as well as others that also have an extraordinary and millenary tradition 
such as Brazil, Mexico, India, Australia, Paraguay, Peru, Bolivia and New Zealand, are committed 
to obtaining full protection concerning traditional medicine, which presents a lack of adequate 
defense mechanisms not only to protect the inventions themselves but also to respect the human 
rights of populations, especially considering that in their globalization context the participation of 
minorities is almost null, meanwhile the State should fight for their interests. 
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More specifically, the intellectual property situation of traditional knowledge in Mexico, 
for example, consists of a complicated question because there is no jurisdiction and the current 
regulations are dispersed in different laws that were previously established and are mostly related 
to what is called in this country as Environmental Law. This absence of legislation to protect 
traditional knowledge is the result of not considering local knowledge, activities and practices as 
formal knowledge. The argument for not recognizing and protecting traditional knowledge is that 
they constitute common heritage or public domain. The situation is worrying. The ayahuasca tea 
is no stranger to this territory, where it is commonly used by “shamans”, who, through the spiritual 
wisdom, are receiving in recent years an increased quest for consultations, becoming a true 
phenomenon in large and small cities of that country. 
At international level, the World Health Organization (WHO) is an institution that has one 
of the broadest programs towards the subject. As previously stated, WHO has a clear definition of 
what the term traditional medicine means, comprehending it as the sum of traditional practices 
and beliefs that guide indigenous people’s techniques for healing and maintaining health22. 
The program developed by this institution seeks to integrate traditional medicine into 
the different national systems for health care, as well as to establish international standards for 
the investigation of traditional medicine and act as a liaison office in the exchange of information. 
Therefore, at the beginning of this century, this organization published the “Traditional medicine 
strategy 2002-2005”, which brings negotiations on the subject between the member countries 
and the different areas involved. Specifically, it aims to reinforce the aforementioned objectives 
of the program as well as to promote in the member countries the regulation of such an important 
area of TK as herbal medicine, to guarantee the use and sustainable development of medicinal 
plants and to protect and preserve indigenous communities’ knowledge in traditional medicine. 
Moreover, since 2000 there is the Intergovernmental Committee of the World 
Intellectual Property Organization (WIPO) on Genetic Resources, Traditional Knowledge and 
Folklore, in which non-governmental organizations, as well as the member countries, actively 
participate, all at the same level of debate, which implies that the involved groups are on equal 
conditions, at least in debate time, since it is well known that the sector represented by indigenous 
people is always the weakest and ultimately the most unprotected in decision-making23. 
The legal form adopted in order to obtain benefits in the exploitation of traditional 
medicine and other uses of biodiversity between indigenous communities and multinational 
companies is by contract par excellence. Biodiversity will be further discussed in this work. 
It should be highlighted that TK include not only medicine, but also crafts, music, painting 
and all other artistic expression produced within indigenous communities. These diverse 
manifestations have in common the normative objective of achieving in the near future adequate 
protection of the intellect and sufficient economic income to their communities, especially 
considering they almost always represent the most undefended and vulnerable sector of the 
population in all areas of law. Although there is already an interesting legislative scope on the 
subject, there is still much to regulate in order to safeguard the interests of this intellectual 
product, and we assume that the existing regulation is scarce. 
Among international legislations, the Convention on Biological Diversity (CBD) or Rio 
Convention, which was opened for signature in the so-called Earth Summit, held in Rio de Janeiro, 
Brazil, on 5 June 1992, coming into force on 29 December 1993. This is the international treaty par 
excellence on the subject. It clearly establishes both forms and mechanisms of protection for 
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indigenous groups and their creations, especially considering a fair distribution of the benefits, 
preserving the main purpose of conservation and proper use of biodiversity. 
The CBD seeks to anticipate, prevent and address the causes of significant reduction or 
loss of biological diversity due to its intrinsic value, as well as the values of its environmental, 
genetic, social, economic, scientific, educational, cultural, recreational and aesthetic components. 
The Convention equally aims to promote cooperation between member States and 
intergovernmental organizations. 
In fact, the debate on traditional knowledge was linked from the beginning with biopiracy 
and access to genetic resources, achieving a first recognition of the rights of nations in 
international law in arts. 3 and 8 of CBD. It has been one of the most difficult themes to regulate 
because of conceptual differences, mostly due to environmental and social peculiarities of the 
countries involved. In addition, there is a major international dispute over genetic resources that 
has been unleashed in the last decades in industrialized countries. In face of that, it has also been 
difficult to develop international and national instruments to enable local and indigenous 
communities and CBD States to have this right. The greatest advance in the international arena 
has been the Nagoya Protocol on Access to Genetic Resources and Fair and Equitable Sharing of 
Benefits Derived from its Utilization in the Convention on Biological Diversity, or the “Nagoya 
Protocol”, signed in Nagoya, Japan, on 29 October 2010, which regulates in detail the provisions 
from CBD on access to traditional knowledge and genetic resources24. 
One of the most prominent conventions that have been signed by several countries, 
including Brazil, is the Convention on Biological Diversity, celebrated in 1992 at the Rio Earth 
Summit. The Convention on Biological Diversity25 was created as a response to the growing 
international awareness for sustainability. The CBD has a new provision in the aforementioned 
articles 3 and 15.1, establishing that the States have the sovereign right to exploit their own 
resources in application of their own environmental policy. Previously, there was predominance 
of the tendency that these resources were a heritage of humanity. For further clarification, we 
quote the Article 3 of Rio Convention: 
Principle. In accordance with the Charter of the United Nations and the principles of 
international law, States have the sovereign right to exploit their own resources in 
application of their own environmental policy and the obligation to ensure that the 
activities conducted under their jurisdiction or their control does not harm the 
environment of other States or areas beyond national jurisdiction26. 
One of the Convention’s objectives speaks directly to this article’s subject: to stimulate 
“the fair and equitable sharing of the benefits arising out of the utilization of genetic resources”, 
which is corroborated by its article 15:.  
Article 15. Access to Genetic Resources 
1. Recognizing the sovereign rights of States over their natural resources, the 
authority to determine access to genetic resources rests with the national 
governments and is subject to national legislation. 
2. Each Contracting Party shall endeavour to create conditions to facilitate access to 
genetic resources for environmentally sound uses by other Contracting Parties and 
not to impose restrictions that run counter to the objectives of this Convention. 
3. For the purpose of this Convention, the genetic resources being provided by a 
Contracting Party, as referred to in this Article and Articles 16 and 19, are only those 
that are provided by Contracting Parties that are countries of origin of such resources 
26 | Revista Brasileira de Direito Animal, e-issn: 2317-4552, Salvador, volume 14, n. 03, p.20-41, Set-Dez 2019 
 
 
or by the Parties that have acquired the genetic resources in accordance with this 
Convention. 
4. Access, where granted, shall be on mutually agreed terms and subject to the 
provisions of this Article. 
5. Access to genetic resources shall be subject to prior informed consent of the 
Contracting Party providing such resources, unless otherwise determined by that 
Party. 
6. Each Contracting Party shall endeavour to develop and carry out scientific research 
based on genetic resources provided by other Contracting Parties with the full 
participation of, and where possible in, such Contracting Parties. 
 
On clause 7 of the aforementioned article, the CBD recognizes the necessity to establish 
a system in which negotiations for the access to biodiversity and TK are done properly, with 
retribution for the original holders of the knowledge. Its third goal brings the concept of sharing 
the benefits conquered with exploration contracts systematically, which will be explored in this 
paper shortly. Besides, we highlight Article 8, which states in subsection J that States should pay 
special attention to the preparation of their respective legislation and that the innovations of 
indigenous communities should be respected, promoting effective compensation. The Article 8 of 
Rio Convention States that: 
Article 8. In-situ Conservation 
Each Contracting Party shall, as far as possible and as appropriate: 
[…] 
(j) Subject to its national legislation, respect, preserve and maintain knowledge, 
innovations and practices of indigenous and local communities embodying 
traditional lifestyles relevant for the conservation and sustainable use of biological 
diversity and promote their wider application with the approval and involvement of 
the holders of such knowledge, innovations and practices and encourage the 
equitable sharing of the benefits arising from the utilization of such knowledge, 
innovations and practices […] 
In other words, the CBD explicitly introduces a “code of conduct” for parties that intend 
to communicate or exchange with indigenous communities in seek of their TK. This is extremely 
relevant for pharmaceutical corporations, considering that, as stated before, they have a history 
of contacting those communities for research and technological advancement purposes. 
Anticipating big corporations’ comportment, the CBD shows an acute concern for indigenous 
communities of developing countries. Articles 20 and 21 are dedicated to further this “code of 
conduct”, establishing comportment guidelines for parties that intend to negotiate with 
communities from these countries27. 
As of July 2018, the Convention on Biological Diversity has the signatures of 168 
countries28, with Brazil being one of them. Trough 42 articles, a preamble and three annexes, the 
CBD is guided by a logic of accessing TRM through sustainability measures29 in order to balance 
power and resources of developed and developing countries and the latter’s people. It also has a 
supplementary agreement, titled Nagoya Protocol, to which Brazil, as of the same date, is not a 
signatory. 
The Nagoya Protocol is dedicated to deepen the comprehension and implementation of 
the CBD’s third objective to promote fairness in benefits sharing from utilization of TK and 
biological material. With 32 articles, a preamble and an annex, the Nagoya Protocol is an 
important reference for corporations that seek to use of environmental and indigenous traditions 
sources to conduct their researches. The Protocol shows its intention is not to prohibit technical 
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advances with the usage of these sources, but with preservation and conscious utilization of 
biodiversity and traditional sources. When it comes to traditional knowledge, the Nagoya Protocol 
dedicates an entire article to the theme: 
Article 12. Traditional Knowledge Associated with Genetic Resources 
1. In implementing their obligations under this Protocol, Parties shall in accordance 
with domestic law take into consideration indigenous and local communities’ 
customary laws, community protocols and procedures, as applicable, with respect to 
traditional knowledge associated with genetic resources. 
2. Parties, with the effective participation of the indigenous and local communities 
concerned, shall establish mechanisms to inform potential users of traditional 
knowledge associated with genetic resources about their obligations, including 
measures as made available through the Access and Benefit-sharing Clearing-House 
for access to and fair and equitable sharing of benefits arising from the utilization of 
such knowledge. 
3. Parties shall endeavour to support, as appropriate, the development by 
indigenous and local communities, including women within these communities, of: 
(a) Community protocols in relation to access to traditional knowledge associated 
with genetic resources and the fair and equitable sharing of benefits arising out of 
the utilization of such knowledge; 
(b) Minimum requirements for mutually agreed terms to secure the fair and 
equitable sharing of benefits arising from the utilization of traditional knowledge 
associated with genetic resources; and 
(c) Model contractual clauses for benefit-sharing arising from the utilization of 
traditional knowledge associated with genetic resources. 
4. Parties, in their implementation of this Protocol, shall, as far as possible, not 
restrict the customary use and exchange of genetic resources and associated 
traditional knowledge within and amongst indigenous and local communities in 
accordance with the objectives of the Convention. 
Particularly on clause 3 of article 12, the Nagoya Protocol evidences the foundations of 
its scope: the logic of a system of fair retribution for TRM explorations agreements. It determines 
that the results of the researches, studies, patents and any other kind of agreement with 
indigenous communities must meet these indigenous people, in order to support development of 
their community. Even though the kind of retribution isn’t explicitly stated, allowing for several 
interpretations of what retribution might be, the article provides a model of how entities with 
more power – be it economic, structural, information or influence – must conduct themselves in 
order to gain fair access to traditional knowledge, including TRM.  
While criticism of the Nagoya Protocol’s text ambiguity has risen30, we see the Nagoya 
Protocol as a positive step towards an ideal system to recognize and to render indigenous 
communities with what they deserve for their contribution to scientific and technological 
advancement. It isn’t to say the Nagoya Protocol has achieved a “state of the ideal”, however, it 
certainly serves as a legal support to defend what should be the norm. 
Since Rio Earth Summit and the CBD, Brazil has shown growing concern over 
sustainability and biodiversity. After hosting the Summit and signing the Convention, Brazil passed 
the provisional measure no. 2.186-16/2001, which was then revoked when the Law no. 13.123 
was passed in 2015, commonly known as The Law of Biodiversity 
In order to achieve the objective established in this paper, an ad hoc working group 
meets periodically, seeking to promote a more active role to indigenous communities to request 
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the government to assure their decisions and start further studies to incorporate these decisions 
gradually in the respective legislations31. 
Another important international instrument to be highlighted is the Convention 169 of 
the International Labour Organization (ILO) on Indigenous and Tribal Peoples, which mentions in 
the Article 15, first paragraph: “The rights of peoples concerned with the natural resources existing 
on their lands should be specially protected. These rights include the right of these peoples to 
participate in the use, administration and conservation of the aforementioned resources” and in 
the second paragraph it clearly explains that: 
[...] if the State owns the minerals or subsoil resources or has rights over other 
resources existing on the land, governments should establish or maintain procedures 
that aim at consulting the peoples concerned in order to determine if and to what 
extent the interests of those peoples would be prejudiced, before undertaking or 
authorizing any program of prospecting or exploitation of the resources existing on 
their lands32 
The convention, moreover, adds that peoples have the obligation to participate 
whenever possible in the resulting benefits as well as the right to receive an equitable 
compensation for any damage suffered as a result of such activities. Clearly it is noticed that, 
according to this legislation, it is not an option, but rather an obligation, for peoples to participate 
in the programs that involve their own resources. 
Focusing now on this investigation, in accordance with the doctrine under study, we want 
to highlight specifically that indigenous communities do not hold the concept of private property 
at a value as high as western society33. Considering the power unbalance between pharmaceutical 
corporations and indigenous communities, pharmaceutical patents that originate from TRM must 
be overviewed with great care. Appropriating traditional medicine, knowledge and biological 
material often results in no result at all for the original source of those materials, a phenomenon 
referred to as “biopiracy” and that has been severely denounced for years. 
Varias organizaciones no gubernamentales (ONGs) critican las aplicaciones 
industriales de los conocimientos tradicionales porque, en muchos casos, las 
empresas farmacéuticas que producen semillas y productos químicos para la 
agricultura practican lo que ellos consideran una "biopiratería masiva y creciente 
contra las comunidades indígenas y locales" (Red del Tercer mundo 1996: 15). La 
biopiratería significa obtener sin consenso los conocimientos tradicionales o los 
recursos biológicos y/o la propiedad de "inventos" derivados de esos conocimientos, 
sin compartir los beneficios. Desde los años ochenta, diversas organizaciones 
internacionales y comunidades étnicas han exigido el reconocimiento de sus 
derechos sobre esos conocimientos (Red del Tercer mundo 1996)34. 
Literature has also referred to the phenomenon as “bioprospecting”, which essentially is 
the practice of patenting traditional knowledge for commercial purposes in a way to counter 
biopiracy. Although similarities and differences between biopiracy and bioprospecting have been 
pointed, critics of the practice defend the two terms serve the same concept35. Shiva’s position is 
that bioprospecting “is merely a sophisticated form of biopiracy” for three main reasons: one, 
biodiversity and traditional knowledge, by definition, cannot be patented, given that they are 
collections of cultural inheritance; two, it essentially is legalizing monopoly over TK and biological 
materials; and finally, this monopoly excludes and does not refer back to these indigenous 
communities at all, resulting in impoverishment of the indigenous communities, who neither have 
access to the biodiversity nor the inventions enabled by such material36. 
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2 The Case Of Ayahuasca Misappropriation 
Ayahuasca is a great example of misappropriation of traditional medicine. In the 1980’s, 
a sample of Ayahuasca was taken from the Amazonian forests in Ecuador and to the U.S. Patent 
and Trademark Office. Claiming the sample to be a new variety of plant, Miller & Co., the company 
that took the sample, obtained the patent of the alleged novelty and every exclusivity rights that 
came with it37. Patented under the name Da Vine (patent number Plant 5,751), Ayahuasca was 
misappropriated38. Only after indigenous people took legal measures against the 
misappropriation, years after it had happened, the patent was revoked39. 
The case of Ayahuasca misappropriation is a clear example of how big corporations will 
seek biodiversity and various forms of traditional knowledge in favor of their own gain. This is not 
to say pharmaceutical patents, or even patents in general, are inherently bad. A patent is a 
relevant tool for social and scientific development. Its logic is to protect the inventor and the 
invention, recognizing the intellectual work that bore valuable fruits for society, so as to encourage 
more industrial technical development40. The relevance of pharmaceutical patents is enormous, 
both on a global and on a local scale – from local communities overall health improvement to 
economic impulsion of entire nations, the system of patents and, therefore, pharmaceutical 
patents, gives way to social growth, technological advance and access to knowledge41. Those are 
central elements for social development and without a cohesive system to protect intellectuality, 
technological, social, scientific and economic advancement can be compromised. 
Nonetheless, pharmaceutical patents, for their importance alone, cannot enjoy of 
absolute prevalence over traditional medicine. The criticism around the communication between 
pharmaceutical corporations and indigenous people’s traditional knowledge does not lie solely on 
patenting techniques inspired by their traditions or biological material that are traditionally used 
in their communities. It lies on how this communication is done and, more specifically, the sum of 
results for both parties after these exchanges. What often happens is that, after the contract is 
celebrated, indigenous people see their knowledge commercialized and the biological material 
that had always been common to their culture scarce. 
What happened with Ayahuasca cannot be tolerated in a system that values justice and 
growth for human kind. What must happen in order to prevent or, at the very least, revert the 
negative effects of this phenomenon, is to put into work a system in which modern medicine can 
be developed whereas traditional medicine can be recognized, allowing for the indigenous people 
that originally detained that kind of knowledge to be compensated for their contribution to 
modern medicine. 
 
 
3 Strategies And Legislations On Protecting Traditional Medicine 
Other than Ayahuasca misappropriation in the 1980’s, distinct cases of misappropriation 
of TRM and biodiversity were denounced. For example, the case of Phytopharm vs. the San and 
Khoe indigenous communities Hoodia plant42, in which the plant, commonly used in TRM, was 
patented without consent and commercialized as a promise to cure obesity. Cases like these 
brought discussion over IPRs and TRM to the center of the public eye internationally. Criticism 
surrounding both biopiracy and bioprospecting (either as two separate concepts or as the latter 
being a device for legalizing the former) gained attention throughout environmentalist 
organizations worldwide. 
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To counter these and other similar practices, as mentioned before, legal measures have 
been taken on a global scale. Returning to the subject of legislation partaking TK and TRM, the 
CBD is certainly one of the most important milestones regarding these types of knowledges, 
biodiversity, and traditions. Those aspects of human heritage cannot be considered inferior or 
unimportant in front of technology, even if the latter’s usage means improvement of those ancient 
knowledges. The Rio Convention seeked to put the subject of their protection in the spotlight, 
with the goal of establishing legal and extralegal directives to guarantee this protection.  
There is criticism on Brazil’s legislation on biodiversity and how bureaucratic it can be, 
going against the very premises of CBD43. Even so, Brazilian law’s scope envisions guidelines for TK 
access, showing there is, at least on paper, worry over the importance of protecting TRM holders 
and their rights. However, Brazil has not signed the Nagoya Protocol – which pointedly speaks of 
TRM and TK exploration. Considering Brazil’s incredible richness of biodiversity and indigenous 
communities with their own traditions and culture, and considering, further, the recent scientific 
study supporting Ayahuasca’s benefits for depression, we believe the lack of signature of The 
Nagoya Protocol by Brazil could be a cause for concern. It is, at very least, paradoxical to what 
Brazil has signed and passed in the past. 
Furthermore, the World Health Organization launched The Traditional Medicine 2014-
2023 Strategy, which is a program that seeks to implement traditional medicine into established 
health systems worldwide, side by side with modern medicine. WHO acknowledges the 
importance of traditional medicine, recognizing as well the importance to protect the intellectual 
property rights of indigenous communities that originally hold the knowledge to TRM (or T&CM – 
Traditional and Complementary Medicine). 
While there is a growing interest in T&CM, there are still many questions about the 
quality and quantity of evidence which supports its utilization. T&CM research 
should use methods which are generally accepted in the evaluation of health 
services, including comparative effectiveness studies and mixedmethod designs. 
There is also a dearth of research and innovation into the various forms of T&CM. In 
order for T&CM to be considered an integral part of health care, it must be supported 
by evidence. This can be achieved by greater research and innovation accompanied 
by a focus on knowledge management, including intellectual property protection 
rights. This, in turn, is likely to encourage innovation and protect traditional 
knowledge. Although T&CM is now a popular global phenomenon, there is still a risk 
that the traditional knowledge for maintaining health and providing health care to 
people in some countries might be lost. This should be brought to the attention of 
the appropriate intellectual property agencies. 
[…] 
Adequate protection of T&CM through conventional intellectual property or sui 
generis rights can help prevent its unauthorized use. Current intellectual property 
frameworks may be used to protect innovations based on T&CM and be extended to 
include appropriate safeguards to prevent the misappropriation of T&CM. Any new 
sui generis protection system ought not only to ensure prior informed consent and 
access and benefit sharing, but also to provide for widespread access to T&CM, while 
encouraging research on T&CM quality, safety and efficacy in order to adapt existing 
treatments and develop new products. Appropriate strategies can also ensure that 
third parties do not gain illegitimate or unfounded intellectual property rights over 
T&CM44. 
It is important to address that none of these conventions or legislations seek to eliminate 
or demonize, by any means, the study of TK or pharmaceutical patents based on TRM. Rather, the 
objective of all these legal tools is to allow for these exchanges between indigenous communities 
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and pharmaceutical corporations to happen, in a way that aligns these practices with ideals of fair 
retribution and recognition. Prohibiting commercialization, exchange or even access to 
biodiversity and TRM would mean prohibiting human society access to better health care products 
and techniques, which is not IPRs’ goal. Conscious conduct when communicating and exchanging 
with these communities have huge potential to be beneficial to both parties, as well to society on 
a global scale. 
 
4 Commerce Équitable: Intellectual Property Rights And Autonomy Of Indigenous People In 
Fairtrade Of Traditional Medicine 
In order to promote development for both pharmaceutical products and indigenous 
communities, a system in which both parties have access to the positive results of such 
interchange must be followed. The CBD and the Nagoya Protocol surround their texts on a concept 
known as benefits-sharing, which can be conceptualized as “a tool to achieve commutative 
justice” through “the action of giving a portion of advantages/profits to others”45. 
A benefit-sharing regime needs not to be grounded on the existence and 
enforcement of IPRs. It may rather operate according to the model established by 
the CBD with regard to the access and use of biological resources, or to other specific 
arrangements46. 
As stated above, IPRs can be valuable tools for promoting social development in many 
aspects. Although benefits-sharing do not necessarily signifies sharing of monetary benefits, it has 
the potential to mean a just system of retribution for indigenous people’s contribution for science 
and pharmaceutical advancement. Even so, when it comes to biodiversity and traditional 
medicine, it must be taken into consideration that the holders of this kind of knowledge don’t 
necessarily deem intellectual property rights more important than their own cultural beliefs and 
morals. 
It isn’t to say indigenous people are unaware of how their culture is perceived outside of 
their community. Rather, the opposite is closer to the truth47. However, individual property rights 
are often considered less than or even illogical when compared to the hallowed morals and merits 
of passing traditions. The spirituality that surrounds their habits and economy, more than a means 
to connect to nature and other humans, is a gift that must be venerated48. 
In a world guided by financial retribution, the indigenous perception might seem 
uncanny, but it is no less worthy of respect. In order to promote respect for these beliefs and 
simultaneously pair up to intellectual property rights dogmatic, there must be a central ideal 
surrounding occurrences in which they meet. To that, the French have a term we deem the most 
appropriate: commerce équitable. 
While fairtrade could be the closest to a faithful translation of the French term, it doesn’t 
quite evoke the core of its purpose. Commerce équitable does not mean monetary fairness to an 
economic transaction, but an entire range of measures that seek to render the negotiation to the 
utmost justice. Sok brings a definition of commerce équitable:  
La définition conventionnelle du commerce équitable – La première définition du 
commerce équitable a été établie par le réseau informel et non permanent de travail 
FINE – en se basant sur les travaux initiaux de quatre grandes organisations du 
commerce équitable (OCE) : FLO, IFAT, NEWS, EFTA. Le commerce équitable est 
défini comme 
« un partenariat commercial, fondé sur le dialogue, la transparence et le respect, 
dont l'objectif est de parvenir à une plus grande équité dans le commerce mondial. 
Il contribue au développement durable en offrant de meilleures conditions 
commerciales et en garantissant les droits des producteurs et des travailleurs 
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marginalisés, tout particulièrement au Sud de la planète. Les organisations du 
commerce équitable (soutenues par les consommateurs) s’engagent activement à 
soutenir les producteurs, à sensibiliser l’opinion et à mener campagne en faveur de 
changements dans les règles et pratiques du commerce international 
conventionnel49. 
Benefits-sharing can encompass other kinds of contribution-retribution relationships 
that do not necessarily mean monetary rendering. Commerce équitable, on the other hand, is 
geared by commercial relationships, though with a more humanitarian approach. Article 60 of 
French Law no. 2005-882 of August 2nd of 2005 affirms that commerce équitable envisions to 
enable and secure economic and social progress for economically vulnerable workers by 
stimulating commercial relations with buyers that under certain conditions that try to ensure 
social responsibility and development50. 
Evidence has shown that commerce équitable can have positive results when adopted by 
traditional communities51. With a philosophy of “trade, not aid”52, commerce équitable provides 
the producers of the commercialized materials with resources and means for achieving success in 
that kind of activity. By minimizing intermediaries between the original holders of the materials 
and its respective buyers, the entryway of the former in the circle of commercial relations is 
facilitated, taxes of products transfer is reduced and the chances of subsistence success is 
augmented53. 
This can be true as well for negotiations between pharmaceutical corporations and 
indigenous people. By utilizing of a system of commerce équitable, not only the intellectual 
property rights of indigenous people will be protected, but they will also be able to actively 
exercise their autonomy as parties of these negotiations. Autonomy for a vulnerable group can 
translate into the first step towards social, economic and intellectual advancement, and neither 
those things are fatally opposite to keeping their traditions. 
Furthermore, these possibilities can also be true for Ayahuasca and the several 
indigenous communities throughout South America that have it as key element of healing and 
religious rituals. The theme of Ayahuasca is delicate for its history with the non-consented 
patenting and usage popularization. However, when it comes to Ayahuasca and the future 
pharmaceutical patents the recent scientific validation can propitiate, the several indigenous 
communities that hold Ayahuasca as part of their traditions and religious rituals might be able to 
assert their will in these negotiations. 
Commerce équitable is a collection of ethic ideals put to practice. From sustainability, to 
economic inequality decrease and fairness of trade, work rendering and autonomy of vulnerable 
communities, the practice of fair trading by French guidelines can be a responsible and positive 
alternative to other forms of exploration of traditional knowledge and biological materials such as 
biopiracy and bioprospecting. It allows the communities that hold these sources to have autonomy 
in what aspect of their culture will be shared and how it will be done, thus allowing possibilities 
for economic and social enhancement along with reinforcement of traditions that date back to 
ancient times. 
 
 
Conclusion 
Ayahuasca is a beverage commonly known for its psychoactive qualities. Recent scientific 
evidence has shown Ayahuasca, for these very same chemical qualities, can be of value for 
patients diagnosed with depression and who are resistant to the usual treatments in modern 
medicine. Ayahuasca is also a sacred beverage for indigenous peoples of the Amazonian region in 
South America, and is commonly used in healing and religious rituals by these people. 
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With the recent scientific validation, Ayahuasca can become a central theme in patenting 
negotiations with pharmaceutical corporations, entities that have a historical conduct of 
misappropriation of natural resources and traditional knowledge of indigenous people for 
commercial gain. In the era of the Convention of Biological Diversity and the Nagoya Protocol, 
such conduct is not acceptable, given that the intellectual property rights of these indigenous 
people over traditional medicine and biological resources that are part of their culture must be 
respected. 
In order to achieve both pharmaceutical and technological advancement whilst still 
maintaining respect for indigenous traditions, a system of consensual sharing and rendering must 
be installed. The closest concept society has to that nowadays is the French system of commerce 
équitable, which provides means for the vulnerable communities to gain autonomy and 
approximates them to potential buyers, thus valuing their own work and reducing gaudy costs of 
transfer and trading. 
The right of indigenous people to self-determine in a world that distances itself more and 
more of their habits is of utmost value. To install practices that allow this kind of autonomy goes 
up to pair with intellectual property rights’ objective, given that commerce équitable has the 
potential to mean better understanding of traditional knowledge and biodiversity’s value for 
modern society, while scientific, technological and pharmaceutical advancement can still be 
achieved through conscious interchange of knowledge and the benefits of its commercialization. 
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